Slides
Page 1
August 3, 2026 Redefining Possibilities in Rare Disease 2026 Second Quarter Financial Results
Page 2
August 3, 2026 Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements 2 This presentation contains forward-looking statements, including, but not limited to, statements related to: sales growth for the company’s combined rare oncology and epilepsy franchises in 2026, Xywav sales in 2026 and rare sleep revenue in 2026; the company’s growth prospects and future financial and operating results, including the company’s 2026 financial guidance and the company’s expectations related thereto; the company’s advancement of pipeline programs and the timing of development activities, regulatory activities, approvals, and submissions related thereto; the potential for a near-term commercial launch of zanidatamab in 1L HER2+ GEA in the U.S., if approved; planned or anticipated clinical trial events, including with respect to initiations, enrollment and data read-outs, and the anticipated timing thereof, including: the second interim OS data from the Phase 3 HERIZON trial of zanidatamab in 1L GEA, the top-line data from the EmpoweHER -BC-303 trial in breast cancer and top-line data from the Phase 3 ACTION trial of Modeyso in recurrent H3 K27M-mutant diffuse glioma; and the company’s development, regulatory and commercialization strategy; the company’s expectations with respect to its regulatory submissions, including its NDA for a cannabidiol oral capsule formulation for potential use in existing approved Epidiolex/Epidyolex formulations; the company’s expectations with respect to its products and product candidates and the potential of the company’s products and product candidates and the potent ial regulatory path related thereto, including zanidatamab's potential to become the HER2-targeted therapy of choice in 1L HER2+ GEA, regardless of PD-L1 status; the company’s capital allocation and corporate development strategy; the potential successful future development, manufacturing, regulatory and commercialization activities; the company’s expectations with respect to its collaborations with third parties, including its collaboration with AbCellera; the company’s ability to realize the commercial potential of its products; the company’s net product sales and goals for net product sales from new and acquired products; the company’s views and expectations relating to its patent portfolio, including with respect to expected patent protection, as well as expectations w ith respect to exclusivity; the company’s clinical trials confirming clinical benefit or enabling regulatory submissions, including the potential of the ongoing Phase 3 ACTION trial to confirm clinical benefit of Modeyso in recurrent H3 K27M-mutant diffuse glioma and extend to use in 1L patients; and other statements that are not historical facts. These forward-looking statements are based on the company’s current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: maintaining or increasing sales of, and revenue from, Xywav, Epidiolex/ Epidyolex, Ziihera, Modeyso, Zepzelca and other lead marketed products; effectively launching and commercializing the company’s other products and product candidates, including zanidatamab in 1L HER2+ GEA, if approved; the successful completion of development and regulatory activities with respect to the company’s product candidates; obtaining and maintaining adequate coverage and reimbursement for the company’s products; the time-consuming and uncertain regulatory approval process, including the risk that the company’s current and/or planned regulatory submissions may not be submitted, accepted or approved by applicable regulatory authorities in a timely manner or at all, including the risk that the zanidatamab in 1L HER2+ GEA may not be approved in a timely manner or at all; the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients; global economic, financial, and healthcare system disruptions and the current and potential future negative impacts to the company’s business operations and financial results; protecting and enhancing the company’s intellectual property rights and the company’s commercial success being dependent upon the company obtaining, maintaining and defending intellectual property protection and exclusivity for its products and product candidates; delays or problems i n the supply or manufacture of the company’s products and product candidates, including due to geopolitical tensions and military conflicts; complying with applicable U.S. and non-U.S. regulatory requirements, including those governing the research, development, manufacturing and distribution of controlled substances; government investigations, legal proceedings and other actions; identifying and consummating corporate development transactions, financing these transactions and successfully integrating acquired products, product candidates and businesses; the company’s ability to realize the anticipated benefits of its collaborations and license agreements with third parties; the sufficiency of the company’s cash flows and capital resources; the company’s ability to achieve targeted or expected future financial performance and results and the uncertainty of future tax, accounting and other provisions and estimates; fluctuations in the market price and trading volume of the company's ordinary shares; and other risks and uncertainties affecting the company, including those described from time to time under the caption “Risk Factors” and elsewhere in the company’s Securities and Exchange Commission filings and reports, including the company's Annual Report on Form 10-K for the year ended December 31, 2025 and future filings and reports by the company. Other risks and uncertainties of which the company is not currently aware may also affect the company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated.
Page 3
August 3, 2026 Transforming Lives. Redefining Possibilities. 3 Non-GAAP Financial Measures To supplement Jazz Pharmaceuticals’ financial results and guidance presented in accordance with U.S. GAAP, the company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures in this presentation. The company presents non-GAAP ANI (ANL) (and the related per share measure) and certain line item components as well as certain non-GAAP adjusted financial measures derived therefrom, including non-GAAP adjusted gross margin percentage and non-GAAP adjusted effective tax rate. Non-GAAP ANI (ANL) (and the related per share measure) and its line item components exclude from GAAP reported net income (loss) (and the related per share measure) and its line item components certain items, as detailed in the reconciliation tables that follow in the Appendix hereto, and in the case of non-GAAP ANI (ANL) (and the related per share measure), adjust for the income tax effect of the non-GAAP adjustments. In this regard, the components of non-GAAP ANI (ANL), including non-GAAP adjusted cost of product sales, SG&A expenses and R&D expenses, are income statement line items prepared on the same basis as, and therefore components of, the overall non-GAAP ANI (ANL) measure. The company believes that each of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors and analysts and that each of these non-GAAP financial measures, when considered together with the company’s financial information prepared in accordance with GAAP, can enhance investors’ and analysts' ability to meaningfully compare the company’s results from period to period and to its forward-looking guidance, and to identify operating trends in the company’s business. In addition, these non-GAAP financial measures are regularly used by investors and analysts to model and track the company’s financial performance. The company’s management also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate the company’s business and to make operating decisions, and compensation of executives is based in part on certain of these non-GAAP financial measures. Because these non-GAAP financial measures are important internal measurements for the company’s management, the company also believes that these non-GAAP financial measures are useful to investors and analysts since these measures allow for greater transparency with respect to key financial metrics the company uses in assessing its own operating performance and making operating decisions. These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the company's consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles in the reconciliation tables that follow. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its non-GAAP financial measures; and the company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. Likewise, the company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by the company in this presentation and the accompanying tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.
Page 4
4 Introduction and Overview Renee Gala President and Chief Executive Officer August 3, 2026
Page 5
August 3, 2026 Strong Execution Across Franchises Drives 2026 Revenue Guidance Increase 2Q26 Execution Highlights Upcoming Milestones Financial Strength 1Shitara et al., The New England Journal of Medicine, May 2026; 2Cannabidiol capsule formulation, if approved, for use within Epidiolex’s existing approved indications (LGS, DS or TSC); 3Double-digit growth based on net product sales, which excludes revenues from high-sodium AG royalties; 4Cash includes cash, equivalents, and investments as of June 30, 2026; 5For the six months ended June 30, 2026; 6Top-line results from the second interim survival analysis for the HERIZON-GEA-01 doublet regimen of zanidatamab + chemotherapy. 5 Strong balance sheet: • Cash4 at end of 2Q26: $2.2B • YTD5 operating cash flow: $824M Robust 2Q26: • Record quarterly revenues of $1.2B (+16% YoY) • Double-digit growth3 from sleep, epilepsy and oncology franchises • Raised full-year 2026 revenue guidance Commercial: • Xywav (+13% YoY) • Epidiolex (+16% YoY) • Zepzelca (+42% YoY) • Prepared to launch zanidatamab in HER2+ 1L GEA R&D: • Phase 3 HERIZON-GEA-01 data published in The New England Journal of Medicine1 • Submitted NDA for cannabidiol capsule formulation2 • Announced collaboration with AbCellera to discover next-generation TCE multispecific antibodies • Ready to launch zanidatamab in GEA; PDUFA date of August 25, 2026 • HERIZON-GEA-01 interim OS data6 3Q26 • Modeyso ACTION study data 1H27 • EmpowHER-BC-303 trial enrolling, data expected late 2027 / early 2028 • Zanidatamab development program continues to progress • Opportunity for additional business development in rare disease
Page 6
6 Commercial Performance Sam Pearce Executive Vice President and Chief Commercial Officer August 3, 2026
Page 7
August 3, 2026 Xywav: Differentiated by Low Sodium; IH Provides Growth Opportunity 1Approximate active Xywav patients exiting quarter; 2Based on 2Q26 Xywav net product sales; 3Rare Sleep franchise consists of Xywav, Xyrem and high-sodium oxybate AG royalties. 10,600 10,725 10,950 11,075 11,275 4,625 4,950 5,225 5,525 5,850 2Q25 3Q25 4Q25 1Q26 2Q26 NET ACTIVE XYWAV PATIENTS1 NarcolepsyIH • Xywav revenue grew 13% YoY in 2Q26; continued momentum with 525 net patient adds in 2Q26 • Benefits of highly efficacious and safer treatment option due to reduced sodium content along with an individualized dosing regimen continue to resonate with patients and HCPs Narcolepsy • Xywav remains the #1 branded treatment for narcolepsy2 Idiopathic Hypersomnia • Continued positive momentum from investments to further build the IH market driving 325 IH net patient adds in 2Q26 Rare sleep3 franchise: • Total rare sleep3 revenue of $544 million in 2Q26 • In 2026, expect total rare sleep3 revenue of $2.025 to $2.125 billion 7 15,225 15,675 16,175 16,600 17,125
Page 8
August 3, 2026 Epidiolex: Development Opportunities for Durable Growth 8 Epidiolex is the #1 branded epilepsy treatment1 • Continued commercial momentum with $292M in 2Q26 revenue Growth opportunities: • Expanded Epidiolex development opportunities with multiple new clinical trials • Submitted NDA for cannabidiol capsule formulation2 to help broaden utilization and increase flexibility for patients • Further data generation, including beyond-seizure benefits from the EpiCom3 study in TSC and nurse-reported responses the BECOME4 caregiver survey in long- term care facilities • JazzCares suite of services including the Nurse Navigator program helps support patients and families through their treatment journey 1Based on 2Q26 Epidiolex net product sales; 2Cannabidiol capsule formulation, if approved, for use in Epidiolex’s currently approved indications: LGS, DS, TSC; 3Eeghen, AM, Thiele, EA, et al. Poster presented at: American Epilepsy Society 2024 Annual Meeting, December 6-10, 2024. Los Angeles, CA; 4Wrobel, N. Poster presented at: American Academy of Neurology 2025 Annual Meeting, April 5-9. San Diego, CA. $252 $292 2Q25 2Q26 +16% YoY Net product sales ($ in millions)
Page 9
August 3, 2026 Zanidatamab: De-Risked Near-Term Opportunity Standard of care in 2L HER2+ BTC 1L HER2+ BTC confirmatory trial ongoing Granted conditional marketing authorization by EC in 2L HER2+ BTC for monotherapy treatment Expanded opportunity across lines of therapy3: • Post T-DXd (Ph 3 EmpowHER-BC-303 trial) • Early BC (Ph 2 EmpowHER-BC-208 trial) • Novel combinations (collaborations with novel TKIs from Boeringher Ingelheim and Iambic) Potential for novel chemo-free regimen for HER2+/HR+ patients3 Ongoing collaborations in early breast cancer: • I-SPY2 Trial4 • MD Anderson collaboration Goal to be the HER2-targeted agent of choice • Ready to launch in 1L GEA on or before PDUFA date of August 25, 2026 • Customer-facing team in place and prepared for launch Biliary Tract Cancer Gastroesophageal Adenocarcinoma Breast Cancer FDA granted Breakthrough Therapy designation for patients with 1L HER2+ GEA Ready to launch in GEA Potential to become the new standard of care for patients with 1L HER2+ GEA regardless of PD-L1 status Opportunity to explore potential in neoadjuvant populations3 9 ~12,000 BTC cases annually1 in U.S., Europe2 and Japan ~150,000 BC cases annually5 in U.S., Europe2 and Japan ~63,000 GEA cases annually1 in U.S., Europe2 and Japan Broad Potential Beyond BTC, GEA, and BC Other HER2-Expressing Cancers Broad potential beyond BTC, GEA and BC in multiple HER2-expressing indications based on compelling clinical activity from early trials6: • Colorectal (Received BTD) • NSCLC • Ovarian • Endometrial • Pancreatic • Bladder • Salivary Gland • Ampullary • Other HER2-expressing solid tumors Ongoing Phase 2 DiscovHER-Pan-206 • Zanidatamab monotherapy in previously-treated patients with no available treatment options 1Incidence sources: Kantar reports, ToGA surveillance report; SEER, cancer.gov; ClearView Analysis; GLOBOCAN, Data on file; 2Major markets, U.K, France, Germany, Spain, Italy; 3Pending regulatory approvals; 4NCT01042379, in collaboration with QuantumLeap Healthcare Collaborative; 5Incidence source estimates derived from multiple sources: Decision Resources Group, Kantar Health, Jazz Market Research, data on file; 6Funda Meric-Bernstam et al, Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study, The Lancet Oncology, Volume 23, Issue 12, 2022, Pages 1558-1570, ISSN 1470-2045, https://doi.org/10.1016/S1470- 2045(22)00621-0.
Page 10
August 3, 2026 Ready for GEA Launch Focus Areas at Launch 1. Clinical Education & Differentiation Establishing the new standard of care: Ziihera + tislelizumab as foundational backbone for HER2+ mGEA, independent of PD-L1 status 2. Accelerated Market Access Leveraging immediate reimbursement: Utilize established, permanent J-code eliminating barriers to launch and driving rapid formulary adoption 3. Commercial & Field Execution Day-one mobilization: cross-functional teams prepared to launch immediately upon FDA approval; capitalize on significant account overlap 4. Seamless Patient Experience Frictionless onboarding: Activating comprehensive JazzCares support services; ensure zero barriers to patient access 10
Page 11
August 3, 2026 Disease State Awareness & Education Branded Campaign Launch Launch Exceeding Expectations 1 2 3 First and only FDA-approved treatment for recurrent H3 K27M- mutant diffuse midline glioma 11 CNS WHO Grade 4 glioma1 The most aggressive form of glioma Invariably lethal with rapid mortality Median OS: ~1 yr from diagnosis2-5 and <6 months after recurrence6 Limited surgical options and no approved therapies for H3 K27M-mutant diffuse midline glioma7,8 Strong HCP awareness and focus on testing driving increasing breadth of adoption Strong engagement with community oncologists; >600 patients have received Modeyso 9 $48M in 2Q26 net product sales $500M+ in U.S. peak sales potential 1Louis DN et al. Neuro Oncol. 2021;23(8):1231–1251; 2Zheng L et al. Am J Surg Pathol. 2022;26:863-871; 3Vuong et al, Frontiers in Oncology March 2022; 4Mackay A et al. Cancer Cell. 2017;32(4):520-537; 5Ostrom QT et al. Neuro Oncol. 2023;25:799-807; 6Bagley et al Cancers 2025, 17(13), 2107; 7Nabors B et al. Neuro Oncol 25(12), 2114–2116, 2023; 8Gajjar A et al. J Natl Compr Canc Netw 2025;23(3):113–130; 9As of June 30, 2026. Modeyso: Strong Initial Uptake and Early Launch Success
Page 12
August 3, 2026 Zepzelca: Focused on 1LM ES-SCLC PIPELINE 12 FDA approved Zepzelca in combination with Tecentriq as first-line maintenance therapy for ES-SCLC in 4Q25 • Growth driven by uptake in the 1LM setting • Opportunity to redefine the treatment paradigm in 1L maintenance • Included in NCCN Guidelines as a Category 1 preferred regimen • Addresses significant unmet need: IMforte trial results1 showed mOS of 13.2 months vs 10.6 months for atezolizumab alone from the point of randomization • Potential to increase duration of therapy with earlier line patients 2026 Dynamics: • Commercial efforts focused on 1LM ES-SCLC • Based on the Phase 3 LAGOON trial results, in alignment with the FDA, in 3Q26 the company will submit a labeling supplement to remove the 2L indication • 1LM indication will not be affected Net product sales ($ in millions) 1IMforte data presented at ASCO 2025, IMforte study done in collaboration with F. Hoffmann-La Roche Ltd. $75 $106 2Q25 2Q26 +42% YoY (Driven by 1LM uptake)
Page 13
13 Research & Development Robert Iannone, M.D., M.S.C.E. Executive Vice President, Global Head of Research & Development, Chief Medical Officer August 3, 2026
Page 14
August 3, 2026 Progress Towards Realizing Full Potential of Zanidatamab Note: Graphical data as presented from the HERIZON-GEA-01 trial by Elimova et.al ASCO GI 2026 1Shitara et al., The New England Journal of Medicine, May 2026. Data Support Zanidatamab as the HER2-targeted Agent of Choice in 1L HER2+ GEA • Zanidatamab + tislelizumab provide benefit regardless of PD-L1 status with 26.4m mOS (+7 months vs. control arm) • Submitted data for potential NCCN Guideline inclusion • Data published in The New England Journal of Medicine1 • Ready for launch in 1L GEA; PDUFA date of August 25, 2026 Focused on maximizing value of zanidatamab: • GEA data de-risks opportunities across HER2+ indications, including ongoing Ph3 trial in metastatic breast cancer • Goal to become the HER2-targeted therapy of choice and cornerstone of future growth for Jazz 14 Results from the Phase 3 HERIZON-GEA-01 Study
Page 15
August 3, 2026 Key Clinical Programs PHASE 1 PHASE 2 PHASE 3 PHASE 4 / REGULATORY Recent / Upcoming Milestones Zanidatamab Interim OS data expected 3Q26; PDUFA date of August 25, 2026 Anticipate top-line data late 2027 / early 2028 Dordaviprone Anticipate interim OS data in 1H27 JZP3507 (ONC206) JZP815 JZP898 Epidiolex (cannabidiol oral solution) New trial New trial Cannabidiol capsule formulation New trial NDA submitted JZP047 Initiated Phase 1 in healthy participants Key Pipeline Programs 1L BTC (HERIZON-BTC-302) Neoadjuvant treatment of locally advanced BC (I-SPY2) RAF & RAS mutant tumors Solid tumors 1L GEA (HERIZON-GEA-01) Breast cancer patients post T-DXd (EmpowHER-BC-303) Pivotal trial for HER2+ solid tumors (DiscovHER-Pan-206) 1L H3 K27M-mutant diffuse glioma (ACTION) 1Phase 2/3 trial utilizing cannabidiol capsule formulation; 2Phase 3b/4 trial. Neoadjuvant and adjuvant BC (EmpowHER-BC-208) 15 Absence Epilepsy Focal-onset seizures Advanced Pheochromocytoma and Paraganglioma (PCPG) Meningioma Juvenile myoclonic epilepsy (JME)1 Developmental and epileptic encephalopathy (DEE) Adults with Lennox-Gastaut syndrome (LGS)2 Capsule formulation
Page 16
16 Financial Performance Phil Johnson Executive Vice President, Chief Financial Officer August 3, 2026
Page 17
August 3, 2026 2Q26 2Q25 Key Commentary Total Revenues $1,208.3M $1,045.7M • 16% increase primarily driven by higher Xywav, Modeyso, Epidiolex, and Zepzelca revenues Non-GAAP Gross Margin1 92.1% 92.7% • Slight decrease primarily due to royalties on Zepzelca and Modeyso Non-GAAP SG&A1 $343.2M $310.3M • 11% increase driven by investments in Modeyso and zanidatamab 1L GEA as well as in building key commercial capabilities Non-GAAP R&D1 $184.9M $167.0M • 11% increase driven by higher clinical study costs, primarily related to zanidatamab Non-GAAP Effective Tax Rate1 15.8% (9.1)% • 2Q26 reflects changes in expected geographic mix of income and expenses; 2Q25 includes impact of Chimerix Acquisition Weighted-Average Diluted Shares 69.4M 61.2M • Increase includes accounting effect of higher stock price on employee stock compensation plans and convertible notes Non-GAAP EPS/LPS1 $5.71 $(8.25) • Includes acquired IPR&D charges of $0.94 and $14.75 per share in 2Q26 and 2Q25, respectively 2Q26 Financial Results Continued Commercial Execution + Financial Discipline 1Non-GAAP Adjusted Gross margin, SG&A expenses, R&D expenses, ETR, and EPS/LPS are non-GAAP financial measures; for further information see "Non-GAAP Financial Measures“ and reconciliation table in the Appendix. 17
Page 18
August 3, 2026 Updated 2026 Guidance (as of August 3, 2026) Prior Guidance (as of May 5, 2026) Key Commentary Total Revenues $4.60 - $4.75B $4.25 - $4.50B • Continue to expect double-digit growth for combined rare oncology + epilepsy revenue • Now expect double-digit growth for Xywav sales • Now expect $2.025B - $2.125B in rare sleep revenue2 Non-GAAP Gross Margin3 90% - 91% 90% - 91% Non-GAAP SG&A3 $1.33 - $1.37B $1.26 - $1.32B • Updated guidance reflects targeted investments to drive further growth of Xywav and Epidiolex and to build key capabilities • Reduction from prior year due to 2025 legal settlements Non-GAAP R&D3 $725 - $775M $725 - $775M Non-GAAP Effective Tax Rate3 11.5% - 13.5% 11.5% - 13.5% Weighted-Average Diluted Shares 69 - 70M 66 – 67M • Increase vs 2025 and prior guidance primarily driven by the effect of higher stock price on convertible notes and employee stock compensation plans 2026 Financial Guidance Raising Revenue and Updating Expense Guidance1 1Guidance provided by Jazz Pharmaceuticals as of August 3, 2026; 2Rare sleep franchise includes Xywav, Xyrem and high-sodium oxybate AG royalty revenues; 3Non-GAAP Adjusted Gross margin, SG&A expenses, R&D expenses, and ETR are non-GAAP financial measures; for further information see "Non-GAAP Financial Measures“ and reconciliation table in the Appendix. 18
Page 19
19 Closing Renee Gala President and Chief Executive Officer August 3, 2026
Page 20
August 3, 2026 Strong Momentum Into 2H26 Published HERIZON-GEA-01 data in The New England Journal of Medicine1 Ready for launch in 1L GEA; PDUFA date of August 25, 2026 Expect EmpowHER-BC-303 trial top-line readout late 2027 / early 2028 Expect Phase 3 1L ACTION trial readout 1H27 Strong initial launch with full-year of commercial sales in 2026 Focused efforts in 1LM ES-SCLC with full-year of commercial sales2 in 2026 Continued commercial execution and data generation Identifying and pursuing opportunities in Rare Disease to drive long-term growth and value Dordaviprone Zanidatamab CommercialResearch and Development Corporate Development 1Shitara et al., The New England Journal of Medicine, May 2026; 2Zepzelca in combination with Tecentriq (atezolizumab). 20
Page 21
21 Appendix August 3, 2026
Page 22
August 3, 2026 Glossary Acronym Definition 1L First-line 1LM First-line maintenance 2L Second-line AG Authorized generic ANI Adjusted net income ANL Adjusted net loss ASCO American Society of Clinical Oncology ASCO GI ASCO Gastrointestinal Cancers Symposium B Billion BC Breast cancer BTC Biliary tract cancer BTD Breakthrough Therapy designation CNS Central nervous system DEE Developmental and epileptic encephalopathy DS Dravet syndrome EC European Commission EPS Earnings per share ES Extensive-stage ETR Effective tax rate FDA U.S. Food and Drug Administration GAAP Generally accepted accounting principles GEA Gastroesophageal adenocarcinoma HCP Healthcare provider HER2 Human epidermal growth factor receptor 2 HR Hormone receptor Acronym Definition IH Idiopathic hypersomnia JME Juvenile myoclonic epilepsy LGS Lennox-Gastaut Syndrome LPS Loss per share M Million mOS Median overall survival NCCN National Comprehensive Cancer Network NDA New drug application NSCLC Non-small cell lung caner OS Overall survival PCPG Pheochromocytoma and Paraganglioma PD-L1 Programmed death ligand 1 PDUFA Prescription Drug User Fee Act Ph 2 / 3 Phase 2 / 3 clinical trial R&D Research and development SCLC Small-cell lung cancer SG&A Selling, general and administrative TCE T-cell engager T-DXd Trastuzumab deruxtecan TKI Tyrosine kinase inhibitor TSC Tuberous sclerosis complex WHO World Health Organization YTD Year-to-date through June 30, 2026 YoY Year-over-year 22
Page 23
August 3, 2026 1Non-GAAP Adjusted net income (loss) (and the related per share measure) are non-GAAP financial measures; for further information, see “Non-GAAP Financial Measures”; 2Integration related expenses with respect to the Chimerix Acquisition. In millions, except per share amounts (unaudited) Three Months Ended June 30, 2026 2025 Net Income Diluted EPS Net Loss Diluted LPS GAAP reported $192.8 $2.78 $(718.5) $(11.74) Intangible asset amortization 170.0 2.45 162.1 2.65 Share-based compensation expense 73.3 1.06 64.5 1.05 Acquisition accounting inventory fair value step-up 16.6 0.24 37.1 0.61 Integration related expenses2 — — 9.4 0.15 Income tax effect of above adjustments (56.3) (0.82) (59.4) (0.97) Non-GAAP adjusted1 $396.4 $5.71 $(504.8) $(8.25) Weighted-average ordinary shares used in diluted per share calculations – GAAP and non- GAAP1 69.4 61.2 Reconciliation of GAAP Reported to Non-GAAP Adjusted Information1 23
Page 24
August 3, 2026 1Non-GAAP Adjusted Gross Margin, SG&A expenses, R&D expenses and ETR are non-GAAP financial measures; for further information, see “Non-GAAP Financial Measures"; 2Integration related expenses with respect to the Chimerix Acquisition. (In millions, except percentages) Three Months Ended June 30, 2026 2025 GAAP gross margin on total revenues 90.4 % 88.9 % Acquisition accounting inventory fair value step-up 1.3 % 3.5 % Share-based compensation expense 0.4 % 0.3 % Non-GAAP gross margin on total revenues1 92.1 % 92.7 % GAAP SG&A expenses $389.2 $358.4 Share-based compensation expense (46.0) (41.0) Integration related expenses2 — (7.1) Non-GAAP SG&A expenses1 $343.2 $310.3 GAAP R&D expenses $207.5 $189.9 Share-based compensation expense (22.6) (20.6) Integration related expenses2 — (2.3) Non-GAAP R&D expenses1 $184.9 $167.0 GAAP ETR 8.6 % 2.3 % Income tax effect of GAAP to non-GAAP reconciling items 7.2 % (11.4)% Non-GAAP ETR1 15.8 % (9.1)% Reconciliation of GAAP Reported to Non-GAAP Adjusted Information1 24
Page 25
August 3, 2026 Reconciliation of GAAP to Non-GAAP Adjusted1 2026 Guidance 1Non-GAAP Adjusted Gross Margin, SG&A expenses, R&D expenses and ETR are non-GAAP financial measures; for further information, see “Non-GAAP Financial Measures". (In millions, except percentages) Projected Range Low High GAAP gross margin on total revenues 89 % 90 % Acquisition accounting inventory fair value step-up 1 % 1 % Non-GAAP gross margin on total revenues1 90 % 91 % GAAP SG&A expenses $1,506 $1,556 Share-based compensation expense (176) (186) Non-GAAP SG&A expenses1 $1,330 $1,370 GAAP R&D expenses $818 $873 Share-based compensation expense (93) (98) Non-GAAP R&D expenses1 $725 $775 GAAP ETR 0 % 10 % Income tax effect of GAAP to non-GAAP reconciling items 11.5 % 3.5 % Non-GAAP ETR1 11.5 % 13.5 % 25